The largest database of trusted experimental protocols

Cd133 2 293c3

Manufactured by Miltenyi Biotec
Sourced in Germany

The CD133/2 (293C3) is a lab equipment product manufactured by Miltenyi Biotec. It is an antibody that recognizes the human CD133 antigen, also known as Prominin-1. CD133 is a pentaspan transmembrane glycoprotein that is expressed on various stem and progenitor cells. The CD133/2 (293C3) antibody can be used for the identification and isolation of CD133-positive cells.

Automatically generated - may contain errors

4 protocols using cd133 2 293c3

1

Flow Cytometry Analysis of Glioblastoma Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 7

Primary human glioblastoma GBM6 cells, U87, or Caco-2 cells were washed three times and suspended in 100 μl of PBS. Cells were stained with either CD133/2 (293C3) (Miltenyi Biotec, Auburn. Calif.) or 100 μl of Hybridoma Clone 7 supernatant, incubated for 30 minutes at 4° C., washed three times, and then suspended in 100 μl of PBS. Cells were further incubated with 10 μl of anti-mouse hylite 647 (1:40 dilution; American Qualex, San Clemente, Calif.) for 30 minutes at 4° C., washed three times, and analyzed by flow cytometry.

+ Open protocol
+ Expand
2

Cytofluorimetric Analysis of Cell Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols
For cytofluorimetric analysis adherent cells were trypsinized, then washed twice in PBS, incubated with 5 μl of fluorochrome-conjugated antibodies for 30 min at 4 °C (5 × 105cells/FACS tube), fixed with 1% formaldehyde solutions for 5 min at 4 °C, centrifuged for 5 min at 1600 rpm and washed once with 1 ml of PBS for 5 min at 1600 rpm. CD133/2 (293C3) (Miltenyi Biotec, Bergisch Gladbach, Germany), HLA-I, NGF-R, ICAM-1, CD20, CXCR4, CD10, c-Kit antibodies (all from BD Biosciences, Franklin Lakes, NJ, USA) conjugated with different fluorescent dyes were used; the unconjugated antibodies Nestin (Novus Biologicals, Minneapolis, USA) and Melan-A/MART-1 (Santa Cruz Biotechnology, Dallas, TX, USA) were used in combination of the goat-anti-mouse IgG-FITC (BD Biosciences) as secondary antibody and used after cell permeabilization. For apoptosis analysis cells were trypsinized, washed in PBS, fixed with 70% ethanol for 45 min at 4 °C, washed in PBS and stained with propidium iodide (50 μg/ml diluted in PBS) and RNAase (250 μg/ml), then stored for at least 3 h at 4 °C before analysis. Flow cytometer analysis was performed by BD FACScan™ System using CellQuest Pro software on a minimum of 5000 events for each sample.
+ Open protocol
+ Expand
3

Isolation and Characterization of HSPC Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mobilized blood or fetal liver–derived CD34+ HSPCs were treated with AAV6 vectors and ZFN mRNA as described above. One or two days post-mRNA electroporation, cells were washed, blocked in FCS (Denville), and stained with the following fluorophore conjugated antibodies: CD34 (581) (BD Biosciences), CD90 (5E10) (BD Biosciences), and CD133/2 (293C3) (Miltenyi Biotec). Cell sorting into subsets based on expression of these markers was performed using a BD FACS Aria II (BD Biosciences), with all compensations performed using Diva software (BD Biosciences). Subsets were defined as primitive (P; CD34+CD133+CD90+), early (E; CD34+CD133+CD90), and committed (C; CD34+CD133CD90) progenitors23 (link). The subsets derived from fetal liver HSPCs were cultured in fetal liver maintenance media, and the subsets derived from mobilized blood HSPCs were maintained in SFEM-II media (Stemcell Technologies, Vancouver, Canada) supplemented with SCF, Flt3L, TPO, and IL-6, for a further 6–7 days. GFP expression was determined in each population by flow cytometry, and site-specific insertion of GFP at either the CCR5 or AAVS1 loci was analyzed by In-Out PCR, as described above.
+ Open protocol
+ Expand
4

Isolation and Characterization of HSPC Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mobilized blood or fetal liver–derived CD34+ HSPCs were treated with AAV6 vectors and ZFN mRNA as described above. One or two days post-mRNA electroporation, cells were washed, blocked in FCS (Denville), and stained with the following fluorophore conjugated antibodies: CD34 (581) (BD Biosciences), CD90 (5E10) (BD Biosciences), and CD133/2 (293C3) (Miltenyi Biotec). Cell sorting into subsets based on expression of these markers was performed using a BD FACS Aria II (BD Biosciences), with all compensations performed using Diva software (BD Biosciences). Subsets were defined as primitive (P; CD34+CD133+CD90+), early (E; CD34+CD133+CD90), and committed (C; CD34+CD133CD90) progenitors23 (link). The subsets derived from fetal liver HSPCs were cultured in fetal liver maintenance media, and the subsets derived from mobilized blood HSPCs were maintained in SFEM-II media (Stemcell Technologies, Vancouver, Canada) supplemented with SCF, Flt3L, TPO, and IL-6, for a further 6–7 days. GFP expression was determined in each population by flow cytometry, and site-specific insertion of GFP at either the CCR5 or AAVS1 loci was analyzed by In-Out PCR, as described above.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!